UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 28, 2020
ONCBIOMUNE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Nevada | 000-52218 | 20-2590810 | ||
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification No.) |
11441 Industriplex Blvd.
Suite 190
Baton Rouge, LA 70809
| (Address of principal executive offices) |
(225) 227-2384
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| registered pursuant to Section 12(b) of the Act: None | |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 28, 2020, the Board of Directors (the “Board”) of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), appointed Mr. Andrew Kucharchuk as a director of the Company, effective immediately. Mr. Kucharchuk has served as the Company’s Chief Financial Officer since 2009 and as its Chief Executive Officer since November 2019.
Mr. Kucharchuk has no family relationships with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Kucharchuk is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K other than his employment agreement with the Company, which is described in the Company’s Annual Report on Form 10-K filed on March 25, 2020. Mr. Kucharchuk has not been, and is not currently expected to be, appointed to any committees of the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ONCBIOMUNE PHARMACEUTICALS, INC. | ||
| By: | /s/ Andrew Kucharchuk | |
| Name: | Andrew Kucharchuk | |
| Title: | Chief Executive Officer, Chief Financial Officer and President | |
| Date: June 1, 2020 | ||